MaaT Pharma: €10.1 Million in Cash, Financing Secured Until End of 2026
As of September 30, 2026, MaaT Pharma had €10.1 million in cash and cash equivalents, compared with €24.9 million as of December 31, 2025. Including the 2025 research tax credit of €3.7 million received in October, the Lyon-based biotech estimates it can fund its operations until the end of December 2026.
Its revenue amounted to €0.5 million in the third quarter and €1.6 million over the first nine months. This amount comes from the compassionate access program, whose operations were transferred to Clinigen in January 2026, which changes the way sales are recorded.
Declining Cash and Financing Secured Until End of December
The cash position published as of September 30 does not take into account the research tax credit, which was collected after the close of the quarter. It is by adding this amount that the company sets its financing horizon at the end of December 2026, based on its current operating plan and financial commitments.
Looking ahead, MaaT Pharma states that it "continues to actively explore financing opportunities with investors as well as strategic partnerships." The end-2026 deadline had already been highlighted by the company in October 2026, in its communication regarding candidate MaaT034.
The Clinigen Contract Brings Published Sales to €1.6 Million Over Nine Months
Since January 2026, MaaT Pharma no longer delivers directly to hospitals: it sells its product to Clinigen, which then supplies healthcare institutions in Europe. The company's revenue therefore now relies on the financial terms of the license agreement, namely a transfer price and royalties.
This transition explains the gap between the net revenue reported over nine months and the €3.3 million it would have reached under the former model. This level is stable compared with the €3.4 million recorded over the first nine months of 2025: the decline in published revenue is due to the change in distribution model, while the underlying business remains stable.
Recent Clinical and Regulatory Data Ahead of the ASH Congress
The publication follows two announcements regarding the clinical portfolio. On October 19, 2026, following a meeting held prior to filing a clinical trial application, the company indicated that the U.S. health authority did not anticipate additional non-clinical safety studies for MaaT034 in solid tumors.
On November 6, 2026, MaaT Pharma commented on the first data from a Phase 2a trial sponsored by AP-HP in metastatic melanoma, in which MaaT013 was well tolerated, with no gain in response. The company specified that these results will inform its development strategy.
By the end of the year, it plans to take part in several conferences, including the SFGM-TC congress in Marseille and the 68th annual ASH meeting in New Orleans, from December 12 to 15, 2026.
The underlying commercial activity thus remains at last year's level, while the continuation of operations beyond the end of December 2026 falls within the financing and partnership discussions the company has initiated.